AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01122121 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprorelin SR
Description: Leuprorelin SR injection
Study NCT01122121 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy 70 +/- 4 Gy
Study NCT01122121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flutamide
Description: Flutamide tablets
Study NCT01122121 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flutamide
Description: Flutamide tablets
Study NCT01890252 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyper CL
Description: The Hyper CL is hyper osmotic contact lens that absorb fluids from the cornea and by that reduces corneal edema.
Study NCT01890252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saline solution
Description: saline solution of 5% NaCl
Study NCT01890252 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: saline solution
Description: saline solution of 5% NaCl
Study NCT02879201 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Slow efficiency dialysis
Description: Slow dialysis 4 times weekly 8 hours CVVHDF predilution mode
Study NCT02624986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idasanutlin
Description: Participants received idasanutlin film-coated tablets orally at a starting dose of 100 mg daily on Days 1 to 5 of each 28-day cycle. Escalation was to occur in at least 50-mg increments, and daily doses greater than or equal to (≥) 400 mg will be split into twice daily dosing.
Study NCT02624986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Participants received a fixed dose of obinutuzumab 1000 mg intravenous (IV) infusion to be given on Days 1, 8 and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 (1 cycle = 28 days). For eligible participants with FL, post-induction treatment was to be given at a dose of 1000 mg via IV infusion on Day 1 once every 2 months for a maximum of up to 24 months.
Study NCT02624986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Participants received a fixed dose of rituximab, 375 mg/m\^2 IV infusion on Day 1 of Cycles 1-6. Post-induction treatment for eligible participants was to be given at a dose of 375 mg/m\^2 IV infusion on Day 1 of every other month for up to 6 months, until disease progression or unacceptable toxicity.
Study NCT00442364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polidocanol (1%) Microfoam (Varisolve)
Description: Varisolve polidocanol 1% microfoam, maximum of 20ml injected into affected great saphenous vein.
Study NCT00442364 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovenous Microfoam Occlusion
Description: Varisolve® polidocanol microfoam injection under duplex guidance to fill proximal and distal great saphenous vein and varicose tributaries.
Study NCT01675167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: Buprenorphine HCl Buccal Film at doses ranging from 150-900 mcg twice daily
Study NCT01675167 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo Buccal Film twice daily
Study NCT02527421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFD01 Spray
Description: DFD-01 (betamethasone dipropionate) Spray, 0.05%
Study NCT01192685 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: TMS will be administered to subjects 5 days a week-typically Monday through Friday, for 6 weeks.
Study NCT01192685 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: near infrared spectroscopy (NIRS)
Description: near infrared spectroscopy (NIRS) will be used to measure the blood flow in the brain
Study NCT03435783 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Electronic Intervention
Description: The brief electronic intervention will allow users to receive normative feedback based on their alcohol use and sexual activity. Users who show interest in changing their behavior will also be asked to create a plan to do so.
Study NCT03435783 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention-Matched Control
Description: Participants will view a video clip on general health promotion that is a similar length as the intervention arm.
Study NCT00853567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proellex
Description: 25 mg oral daily dose vs. 50 mg oral daily dose vs. placebo
Study NCT00853567 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo
Study NCT04215497 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PSSE
Description: Physiotherapeutic Scoliosis-Specific Exercises (PSSE) group will receive exercise for 30-40 mins in a day, twice in a week, totally 8 weeks and 16 hours.~Control group will be taught the basic elements of corrective exercises and want them to do the practising during 8 weeks at home.
Study NCT02452515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1142524
Description: 5 mg BAY1142524 or placebo given as 5 mg IR tablet twice daily for 2 weeks
Study NCT02452515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1142524
Description: 10 mg BAY1142524 or placebo given as 2 x 5 mg IR tablets twice daily as for 2 weeks
Study NCT02452515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1142524
Description: 25 mg BAY1142524 or placebo given as 5 x 5 mg IR tablets twice daily for 2 weeks
Study NCT02452515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1142524
Description: 50 mg BAY1142524 or placebo given 1 x 50 mg IR tablet once daily for 2 weeks
Study NCT02452515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The patients will be treated orally with combinations of IR tablets containing placebo to achieve the indicated dosages.
Study NCT01955629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept AVE0005
Description: Pharmaceutical form: Concentrate for solution for infusion; Route of administration: Intravenous
Study NCT01955629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Pharmaceutical form: Concentrate for solution for infusion; Route of administration: Intravenous
Study NCT01955629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Pharmaceutical form: Tablets; Route of administration: Oral
Study NCT02758483 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control diet
Description: Diet with a little quantity of sugars (30.40g; 12.7% of total carbohydrates of the diet).
Study NCT02758483 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Test Diet
Description: Diet with foods containing moderate quantity of sucrose in composition (80.22g; 30.2% of total carbohydrates of the diet).
Study NCT02259088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab (RFB002)
Description: Ranibizumab 0.5 mg/0.05 mL for intravitreal injection
Study NCT02259088 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser
Description: Laser photocoagulation according to Early Treatment Diabetic Retinopathy Study (ETDRS) guidelines
Study NCT02259088 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sham injection
Description: Imitation of an intravitreal injection consisting of an empty vial and an injection syringe without a needle
Study NCT02259088 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham laser
Description: Imitation of an active laser
Study NCT03100552 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Endoscopic imaging
Description: Analysis of the presence of dysplasia within sessile serrated polyps (SSP) using endoscopic imaging (high definition white light +- narrow band imaging)
Study NCT01441362 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 90 degrees rotation
Description: Double-lumen tube intubation with 90 degrees rotation
Study NCT01441362 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 180 degrees rotation
Description: Double-lumen tube intubation with 180 degrees rotation
Study NCT00220636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Aripiprazole dose ranging from 5 to 30 mg/day, augmenting antidepressant treatment. Aripiprazole is used as an augmenting medication on an open label basis for patients on antidepressant medication who continue to have depressive symptoms. This is an open label case series in which all subjects receive aripiprazole augmentation. There is no comparator group.
Study NCT02709382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefepime and Tazobactam combination
Study NCT05532306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin 400 mg film coated tablet (1*400mg)
Description: an immediate release film-coated tablet containing 400 mg Ribavirin
Study NCT05532306 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Copegus® 200 mg film coated tablet (2*200mg)
Description: an immediate release film-coated tablet containing 200 mg Ribavirin
Study NCT04321707 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 15O-H2O PET/MR
Description: All included patients will have a 15O-H2O PET/MR scan performed at baseline and a scan performed after NAC, prior to cystectomy.
Study NCT00677989 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic appendectomy
Description: laparoscopic appendectomy:did appendectomy by laparoscopic manipulation
Study NCT00677989 — intervention group
Intervention type: PROCEDURE
Intervention: Open appendectomy
Description: open appendectomy: did appendectomy by laparotomy
Study NCT03208985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Use Phase (Ulipristal Acetate, 30 mg)
Description: All subjects enrolled in the use phase of this open-label study will be given the opportunity to purchase and take 30 mg of ulipristal acetate.~Subjects are to use the investigational product based on their understanding of the directions on the outer packaging including Drug Facts Label and inside the product packaging (in the Consumer Information Leaflet).
Study NCT00310661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarizotan
Description: The dose of sariztan HCI for each patient in the drug arm will be given 2mg b.i.d. orally during the first 4 weeks of treatment. If efficacy is inadequate and there are no safety concerns, the option to raise the dose to 5mg b.i.d is given. After 8 weeks of treatment, the option to raise the dose to 7mg bid is given. Dose may remain the same or may be decreased again to the previous dose.
Study NCT00310661 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for each patient randomized to the placebo arm will be given placebo (oral, twice daily) in a pill form for 12 weeks
Study NCT03760861 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prototype Microcapsule Treatment
Description: The subject will be sedated and using an endoscope, a prototype microcapsule will be placed into the gastric corpus. Then, an external handheld magnet will be applied to inflate the balloon encapsulated in the microcapsule. Upon ascertaining the full inflation based on the endoscopic visualization, the investigator will wait another 10 minutes after that to observe how the subject feels before manually puncturing the balloon with needle knife, and retrieving the punctured balloon with the RothNet through the mouth.
Study NCT02940314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIP1503
Study NCT02940314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP1103
Study NCT06328413 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: photobiomodulation
Description: Photobiomodulation application at different extraoral and intraoral points for 60 seconds with a wavelength of 940 nm in repeated sessions after the extraction of third molar
Study NCT06328413 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Leukocyte and Platelet Rich Fibrin
Description: Leukocyte and platelet rich fibrin ( blood product centrifuged for 12 minutes at 2700rpm) application after third molar extraction, single session.
Study NCT01497366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Sofosbuvir 400 mg (2 × 200 mg tablets) administered orally once daily
Study NCT01497366 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG
Description: Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection
Study NCT01497366 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RBV
Description: Ribavirin (RBV) administered as 200 mg tablets up to 1200 mg in a divided daily dose~* Dose of sofosbuvir+RBV group based on baseline weight: \< 75kg = 1000 mg and ≥ 75 kg = 1200 mg~* Dose of PEG+RBV group: 800 mg
Study NCT01497366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Ribavirin (RBV) administered as 200 mg tablets up to 1200 mg in a divided daily dose~* Dose of sofosbuvir+RBV group based on baseline weight: \< 75kg = 1000 mg and ≥ 75 kg = 1200 mg~* Dose of PEG+RBV group: 800 mg
Study NCT04207619 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hyperinsulinemic-hypoglycemic clamp
Description: An intravenous catheter will be placed in an antecubital vein for infusion of insulin and glucose. A second catheter will be placed retrograde in a dorsal vein of the contra-lateral hand for blood withdrawal. The hand will be placed in a heating box or pad at 70°C for arterialization of venous blood. A primed infusion of regular insulin (120 mU/min/m2) will be initiated and continued for approximately 2 hours. Beginning 20 minutes prior to the start of the insulin infusion, arterialized venous blood glucose will be measured at 5 minute intervals via a Hemocue or YSI analyzer. Following initiation of insulin infusion, blood glucose will be allowed to fall to 50 mg/dL and then maintained at this level using a variable infusion of exogenous dextrose (20% solution). Our goal is to achieve steady-state (blood glucose stabilized at 50 +/- 5 mg/dL) within the first 45 minutes following the start of insulin infusion.
Study NCT04207619 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 13C-MRS procedure/Acetate infusion
Description: Glial metabolism will be measured via MRS utilizing a simultaneous intravenous infusion of 13C labeled acetate. An intravenous catheter will be placed in a vein of each arm, one to infuse 13C-acetate and the other to draw blood samples
Study NCT03904992 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive web app
Description: Access to a progressive web app for the promotion of healthy habits in preescholers through the participant's smatphone
Study NCT02897570 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glucose
Description: 50g of glucose dissolved in 250 to 300ml of water was drunk. Prior and upon completion of each glucose tolerance test, an EEG was performed.
Study NCT02897570 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milk & Cereals
Description: A breakfast (B1) including a glass of milk (125ml) and 30 g-corn flakes was consumed. Prior and upon completion of each tolerance test, an EEG was performed
Study NCT02897570 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milk, apple & snack
Description: A breakfast (B2) including a glass of milk (220ml), an apple (200g), a cream chocolate filled sponge cake (30g) was consumed. Prior and upon completion of each meal tolerance test, an EEG was performed.
Study NCT02897570 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milk, apple & bread w/ cream
Description: A breakfast (B3) including a glass of milk (125ml), an apple (150g), bread (50g, hazelnut chocolate cream (15g) was consumed. Prior and upon completion of each meal tolerance test, an EEG was performed.
Study NCT02897570 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EEG_pre
Description: Electroencephalography (EEG) was performed prior each tolerance test to assess frontal P300-evoked potentials
Study NCT02897570 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG_pre
Description: Electroencephalography (EEG) was performed prior each tolerance test to assess frontal P300-evoked potentials
Study NCT02897570 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EEG_post
Description: Electroencephalography (EEG) was performed upon completion of each tolerance test to assess frontal P300-evoked potentials
Study NCT02897570 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG_post
Description: Electroencephalography (EEG) was performed upon completion of each tolerance test to assess frontal P300-evoked potentials
Study NCT02184624 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELLIPTA
Description: Dry powder inhaler (placebo) with two blister strips. One placebo strip containing lactose monohydrate and a second placebo strip containing lactose monohydrate blended with magnesium stearate.
Study NCT02184624 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DISKUS/ACCUHALER
Description: Placebo inhaler with one blister strip containing lactose monohydrate.
Study NCT02184624 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MDI
Description: Placebo inhaler containing propellant (1,1,1, 2-Tetrafluoroethane).
Study NCT02184624 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TURBUHALER
Description: Placebo inhaler containing lactose monohydrate.
Study NCT02184624 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HANDIHALER
Description: Placebo inhaler containing lactose monohydrate in a capsule.
Study NCT02184624 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BREEZEHALER
Description: Placebo inhaler containing lactose monohydrate in a capsule.
Study NCT01996761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: porcine brain peptide (Cerebrolysin)
Study NCT01996761 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00946153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: In the Dose-Escalation Component of the study, lenvatinib will be administered as continuous once-daily oral dosing. Dose-escalation will occur based on safety information obtained during Cycle 1. The recommended dose for the Expansion Component of the study will use the MTD in Cycle 1.
Study NCT02587273 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fentanyl
Description: In this study there will be no administration of an investigational product per study protocol. The dosage of fentanyl will be according to the ICU's established procedures and the treating physician's judgment. The specific dose of fentanyl given to each patient will differ extensively. By routine, the ICU's in our hospital usually dose the fentanyl infusion as 0,5 - 6 μg/kg/hrs (kg = Ideal Body Weight). The intervention in this study will be a per protocol cessation in administration of fentanyl over a 6 hours period. Arterial blood samples, urine samples, pre and post filter samples and samples from dialysate will be collected during this 6 hours. If the patient needs opioid analgesia during the period, alternative opioid analgesia will be given.
Study NCT01774409 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Blood and tumor samples
Description: Genetic: Establishment of the genetic and immunologic profile~Whole blood sampling :~* 1 tube for the constitutional DNA extraction;~* 3 tubes for ancillary studies and research.~Collection of the available archival tumor sample (frozen or FFPE). If there's no available sample, the investigator will prescribe a biopsy of a reachable lesion.~With the established profile, recommendations will be given by a multidisciplinary molecular board.
Study NCT02759367 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High potassium diet
Description: An increase in consumption of high potassium fruits and vegetables
Study NCT02496052 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dried biological amnion graft
Description: Uterine application of amnion membrane following hysteroscopic adhesiolysis. Other Name: Human amnion membrane
Study NCT02496052 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Foley balloon
Description: Device: Foley balloon Uterine application of Foley balloon
Study NCT02496052 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foley balloon
Description: Device: Foley balloon Uterine application of Foley balloon
Study NCT02496052 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: estradiol valerate tablets+dydrogesterone Tablets
Description: oral estradiol valerate tablets+dydrogesterone Tablets
Study NCT02496052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estradiol valerate tablets+dydrogesterone Tablets
Description: oral estradiol valerate tablets+dydrogesterone Tablets
Study NCT04483648 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Home exercises were performed three times in a week for six weeks. Home exercises included range of motion exercises, coordination exercises and strengthening exercises. Repeats and durations of the exercises increased every week to provide progression.
Study NCT04120519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide combined with dexamethasone and cyclophosphamide
Description: TCD
Study NCT01821560 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baclofen
Study NCT01821560 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo